SEQUENCE LISTING

<110> James M. Anderson
Christina M. Van Itallie

<120> Human Occludin, Its Uses and Enhancement of Drug Absorption Using Occludin Inhibitors

<130> OCR-754.CIP

<140> US 09/891,064
<141> 2001-06-25

<150> US 09/142,732
<151> 1998-09-15

<160> 6
<170> MS DOS

<210> 1

<211> 2312

<212> DNA

<213> Homo sapiens

<220>

<221> mat_peptide

<222> complete sequence

<223> human occludin

<400> 1

gcctctctcc atcagacacc ccaaggttcc atccgaagca ggcggagcac 50
cgaacgcacc ccggggtggt cagggacccc catccgtgct gccccctagg 100
agcccgcgcc tctcctctgc gccccgcctc tcgggccgca acatcgcgcg 150
gttcctttaa cagcgcgctg gcagggtgtg ggaagcagga ccgcgtcctc 200
ccgccccctc ccatccgagt ttcaggtgaa ttggtcaccg agggaggagg 250
ccgacacacc acacctacac tcccgcgtcc acctctccct ccctgcttcc 300
tcttggcgga ggcggcagga accgagagcc aggtccagag cgccgaggag 350
ccggtctagg acgcagcaga ttggtttatc ttggaagcta aagggcattg 400
ctcatcctga agatcagctg accattgaca atcagccatg tcatccaggc 450
ctcttgaaag tccacctcct tacaggcctg atgaattcaa accgaatcat 500
tatgcaccaa gcaatgacat atatggtgga gagatgcatg ttcgaccaat 550
gctctctcag ccagcctact ctttttaccc agaagatgaa attcttcact 600
tctacaaatg gacctctcct ccaggagtga ttcggatcct gtctatgctc 650
attattgtga tgtgcattgc catctttgcc tgtgtggcct ccacgcttgc 700
ctgggacaga ggctatggaa cttccctttt aggaggtagt gtaggctacc 750
cttatggagg aagtggcttt ggtagctacg gaagtggcta tggctatggc 800
tatggttatg gctatggcta cggaggctat acagacccaa gagcagcaaa 850
gggcttcatg ttggccatgg ctgccttttg tttcattgcc gcgttggtga 900

```
tctttgttac cagtgttata agatctgaaa tgtccagaac aagaagatac  950
tacttaagtg tgataatagt gagtgctatc ctgggcatca tggtgtttat 1000
tgccacaatt gtctatataa tgggagtgaa cccaactgct cagtcttctg 1050
gatctctata tggttcacaa atatatgccc tctgcaacca attttataca 1100
cctgcagcta ctggactcta cgtggatcag tatttgtatc actactgtgt 1150
tgtggatccc caggaggcca ttgccattgt actggggttc atgattattg 1200
tggcttttgc tttaataatt ttctttgctg tgaaaactcg aagaaagatg 1250
gacaggtatg acaagtccaa tattttgtgg gacaaggaac acatttatga 1300
tgagcagccc cccaatgtcg aggagtgggt taaaaatgtg tctgcaggca 1350
cacaggacgt gccttcaccc ccatctgact atgtggaaag agttgacagt 1400
cccatggcat actcttccaa tggcaaagtg aatgacaagc ggttttatcc 1450
agagtcttcc tataaatcca cgccggttcc tgaagtggtt caggagcttc 1500
cattaacttc gcctgtggat gacttcaggc agcctcgtta cagcagcggt 1550
ggtaactttg agacaccttc aaaaagagca cctgcaaagg gaagagcagg 1600
aaggtcaaag agaacagagc aagatcacta tgagacagac tacacaactg 1650
gcggcgagtc ctgtgatgag ctggaggagg actggatcag ggaatatcca 1700
cctatcactt cagatcaaca aagacaactg tacaagagga attttgacac 1750
tggcctacag gaatacaaga gcttacaatc agaacttgat gagatcaata 1800
aagaactctc ccgtttggat aaagaattgg atgactatag agaagaaagt 1850
gaagagtaca tggctgctgc tgatgaatac aatagactga agcaagtgaa 1900
gggatctgca gattacaaaa gtaagaagaa tcattgcaag cagttaaaga 1950
gcaaattgtc acacatcaag aagatggttg gagactatga tagacagaaa 2000
acatagaagg ctgatgccaa gttgtttgag aaattaagta tctgacatct 2050
ctgcaatctt ctcagaaggc aaatgacttt ggaccataac cccggaagcc 2100
aaacctctgt gagcatcaca aagttttggg ttgctttaac atcatcagta 2150
ttgaagcatt ttataaatcg cttttgataa tcaactgggc tgaacaactc 2200
caattaagga ttttatgctt taaacattgg ttcttgtatt aagaatgaaa 2250
tactgtttga ggtttttaag ccttaaagga aggttctggt gtgaactaaa 2300
ctttcacacc cc                                          2312
```

<210> 2

<211> 522

<212> PRT

<213> Homo sapiens

<220>

<221> peptide

<222> complete sequence

<223> human occludin

<400> 2

```
Met Ser Ser Arg Pro Leu Glu Ser Pro Pro Pro Tyr Arg Pro Asp
                  5                  10                  15

Glu Phe Lys Pro Asn His Tyr Ala Pro Ser Asn Asp Ile Tyr Gly
                 20                  25                  30

Gly Glu Met His Val Arg Pro Met Leu Ser Gln Pro Ala Tyr Ser
                 35                  40                  45
```

```
Phe Tyr Pro Glu Asp Glu Ile Leu His Phe Tyr Lys Trp Thr Ser
                 50                  55                  60

Pro Pro Gly Val Ile Arg Ile Leu Ser Met Leu Ile Ile Val Met
                 65                  70                  75

Cys Ile Ala Ile Phe Ala Cys Val Ala Ser Thr Leu Ala Trp Asp
                 80                  85                  90

Arg Gly Tyr Gly Thr Ser Leu Leu Gly Gly Ser Val Gly Tyr Pro
                 95                 100                 105

Tyr Gly Gly Ser Gly Phe Gly Ser Tyr Gly Ser Gly Tyr Gly Tyr
                110                 115                 120

Gly Tyr Gly Tyr Gly Tyr Gly Tyr Gly Gly Tyr Thr Asp Pro Arg
                125                 130                 135

Ala Ala Lys Gly Phe Met Leu Ala Met Ala Ala Phe Cys Phe Ile
                140                 145                 150

Ala Ala Leu Val Ile Phe Val Thr Ser Val Ile Arg Ser Glu Met
                155                 160                 165

Ser Arg Thr Arg Arg Tyr Tyr Leu Ser Val Ile Ile Val Ser Ala
                170                 175                 180

Ile Leu Gly Ile Met Val Phe Ile Ala Thr Ile Val Tyr Ile Met
                185                 190                 195

Gly Val Asn Pro Thr Ala Gln Ser Ser Gly Ser Leu Tyr Gly Ser
                200                 205                 210

Gln Ile Tyr Ala Leu Cys Asn Gln Phe Tyr Thr Pro Ala Ala Thr
                215                 220                 225

Gly Leu Tyr Val Asp Gln Tyr Leu Tyr His Tyr Cys Val Val Asp
                230                 235                 240

Pro Gln Glu Ala Ile Ala Ile Val Leu Gly Phe Met Ile Ile Val
                245                 250                 255

Ala Phe Ala Leu Ile Ile Phe Phe Ala Val Lys Thr Arg Arg Lys
                260                 265                 270

Met Asp Arg Tyr Asp Lys Ser Asn Ile Leu Trp Asp Lys Glu His
                275                 280                 285

Ile Tyr Asp Glu Gln Pro Pro Asn Val Glu Glu Trp Val Lys Asn
                290                 295                 300

Val Ser Ala Gly Thr Gln Asp Val Pro Ser Pro Pro Ser Asp Tyr
                305                 310                 315

Val Glu Arg Val Asp Ser Pro Met Ala Tyr Ser Ser Asn Gly Lys
                320                 325                 330
```

```
Val Asn Asp Lys Arg Phe Tyr Pro Glu Ser Ser Tyr Lys Ser Thr
                335                 340                 345

Pro Val Pro Glu Val Val Gln Glu Leu Pro Leu Thr Ser Pro Val
                350                 355                 360

Asp Asp Phe Arg Gln Pro Arg Tyr Ser Ser Gly Gly Asn Phe Glu
                365                 370                 375

Thr Pro Ser Lys Arg Ala Pro Ala Lys Gly Arg Ala Gly Arg Ser
                380                 385                 390

Lys Arg Thr Glu Gln Asp His Tyr Glu Thr Asp Tyr Thr Thr Gly
                395                 400                 405

Gly Glu Ser Cys Asp Glu Leu Glu Glu Asp Trp Ile Arg Glu Tyr
                410                 415                 420

Pro Pro Ile Thr Ser Asp Gln Gln Arg Gln Leu Tyr Lys Arg Asn
                425                 430                 435

Phe Asp Thr Gly Leu Gln Glu Tyr Lys Ser Leu Gln Ser Glu Leu
                440                 445                 450

Asp Glu Ile Asn Lys Glu Leu Ser Arg Leu Asp Lys Glu Leu Asp
                455                 460                 465

Asp Tyr Arg Glu Glu Ser Glu Glu Tyr Met Ala Ala Ala Asp Glu
                470                 475                 480

Tyr Asn Arg Leu Lys Gln Val Lys Gly Ser Ala Asp Tyr Lys Ser
                485                 490                 495

Lys Lys Asn His Cys Lys Gln Leu Lys Ser Lys Leu Ser His Ile
                500                 505                 510

Lys Lys Met Val Gly Asp Tyr Asp Arg Gln Lys Thr
                515                 520
```

<210> 3

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<221> peptide

<223> construct used in experiments

<400> 3

Cys Asp Arg Gly Tyr Gly Thr Ser Leu Leu Gly Gly Ser Val Gly
5 10 15

Tyr Pro Tyr Gly Gly Ser Gly Phe Gly
20

<210> 4

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<221> peptide

<223> construct used in experiments

<400> 4

Cys Ser Tyr Gly Ser Gly Tyr Gly Tyr Gly Tyr Gly Tyr Gly Tyr
5 10 15

Gly Tyr Gly Gly Tyr Thr Asp Pro Arg
20

<210> 5

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> peptide

<223> construct used in experiments

<400> 5

Asn His Tyr Ala Pro Ser Asn Asp Ile Tyr Gly Gly Glu Met Val
5 10 15

His Arg Pro Met Leu
20

<210> 6

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> peptide

<223> construct used in experiments

<400> 6

Ala Ser Gln Gln Val Tyr Arg Lys Asp Pro Cys
5 10